Vivus Obesity Pill Scores With Phase III Data, But Still Faces Major Market Hurdles

Qnexa combines two generics, but Vivus Chief Operating Officer Peter Tam says: "We are not concerned about generic substitution."

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet